Evotec SE
EVO3.720USD
+0.030+0.81%
收盤 07/22, 16:00（美東）報價延遲15分鐘
1.32B總市值
虧損本益比TTM
關於 Evotec SE 公司
Evotec SE 是一家總部位於德國的藥物研發公司。該公司通過與製藥和生物技術公司、學術機構、患者組織和風險投資公司建立研究聯盟和開發夥伴關係，致力於開發新藥品。藥物研發解決方案以按服務收費、綜合藥物研發聯盟、開發夥伴關係、候選藥物許可和諮詢安排的形式提供。Evotec SE 的業務涉及多個領域，包括神經科學、糖尿病和糖尿病併發症、疼痛和炎症、腫瘤學、傳染病、呼吸系統疾病和纖維化。其產品線涵蓋一系列治療領域，例如中樞神經系統失眠、慢性咳嗽、免疫學和炎症、女性健康子宮內膜異位症、腎病學、皮膚病、纖維化疾病和抗病毒等。
公司簡介
公司代碼EVO
公司名稱Evotec SE
上市日期Oct 11, 1999
成立日期2019
CEODr. Christian Wojczewski
員工數量4827
證券類型Ordinary Share
年結日Oct 11
公司地址Essener Bogen 7
城市HAMBURG
上市交易所OMX Nordic Exchange Stockholm AB - cash
國家Germany
郵編22419
電話4940560810
網址https://www.evotec.com/
公司代碼EVO
上市日期Oct 11, 1999
成立日期2019
公司高階主管
名稱
名稱/職務
職務
持股
持股變動
Prof. Dr. Iris Loewfriedrich
Prof. Dr. Iris Loewfriedrich
Independent Chairwoman of the Supervisory Board
Independent Chairwoman of the Supervisory Board
--
--
Mr. Volker Braun
Mr. Volker Braun
Senior Vice President, Head of Global Investor Relations and ESG
Senior Vice President, Head of Global Investor Relations and ESG
--
--
Mr. Wesley Wheeler
Mr. Wesley Wheeler
Member of the Supervisory Board
Member of the Supervisory Board
--
--
Dr. Christian Wojczewski
Dr. Christian Wojczewski
Chief Executive Officer, Member of the Management Board
Chief Executive Officer, Member of the Management Board
--
--
Dr. Duncan Mchale
Dr. Duncan Mchale
Member of the Supervisory Board
Member of the Supervisory Board
--
--
Ms. Camilla Macapili Languille
Ms. Camilla Macapili Languille
Independent Member of the Supervisory Board
Independent Member of the Supervisory Board
--
--
Dr. Constanze Ulmer-Eilfort
Dr. Constanze Ulmer-Eilfort
Independent Member of the Supervisory Board
Independent Member of the Supervisory Board
--
--
Mrs. Aurelie Dalbiez
Mrs. Aurelie Dalbiez
Chief People Officer, Member of the Management Board
Chief People Officer, Member of the Management Board
--
--
Dr. Cord Dohrmann, Ph.D.
Dr. Cord Dohrmann, Ph.D.
Chief Scientific Officer, Member of the Management Board
Chief Scientific Officer, Member of the Management Board
--
--
Ms. Laetitia Rouxel
Ms. Laetitia Rouxel
Chief Financial Officer, Member of the Management Board
Chief Financial Officer, Member of the Management Board
--
--
查看更多
名稱
名稱/職務
職務
持股
持股變動
Prof. Dr. Iris Loewfriedrich
Prof. Dr. Iris Loewfriedrich
Independent Chairwoman of the Supervisory Board
Independent Chairwoman of the Supervisory Board
--
--
Mr. Volker Braun
Mr. Volker Braun
Senior Vice President, Head of Global Investor Relations and ESG
Senior Vice President, Head of Global Investor Relations and ESG
--
--
Mr. Wesley Wheeler
Mr. Wesley Wheeler
Member of the Supervisory Board
Member of the Supervisory Board
--
--
Dr. Christian Wojczewski
Dr. Christian Wojczewski
Chief Executive Officer, Member of the Management Board
Chief Executive Officer, Member of the Management Board
--
--
Dr. Duncan Mchale
Dr. Duncan Mchale
Member of the Supervisory Board
Member of the Supervisory Board
--
--
Ms. Camilla Macapili Languille
Ms. Camilla Macapili Languille
Independent Member of the Supervisory Board
Independent Member of the Supervisory Board
--
--
收入明細
單位: USD更新時間: 7月6日 週日
單位: USD更新時間: 7月6日 週日
FY2024
FY2023
暫無數據
地區USD
名稱
營收
佔比
United States
482.23M
55.94%
Switzerland
117.94M
13.68%
United Kingdom
100.06M
11.61%
Rest of the world
89.00M
10.32%
Germany
35.59M
4.13%
Other
37.16M
4.31%
業務
地區
暫無數據
股東統計
更新時間: 7月13日 週日
更新時間: 7月13日 週日
持股股東
股東類型
持股股東
持股股東
佔比
Mubadala Investment Company PJSC
1.29%
Wellington Management Company, LLP
0.54%
BlackRock Institutional Trust Company, N.A.
0.42%
DCF Advisers, LLC
0.21%
Morgan Stanley Smith Barney LLC
0.02%
Other
97.52%
持股股東
持股股東
佔比
Mubadala Investment Company PJSC
1.29%
Wellington Management Company, LLP
0.54%
BlackRock Institutional Trust Company, N.A.
0.42%
DCF Advisers, LLC
0.21%
Morgan Stanley Smith Barney LLC
0.02%
Other
97.52%
股東類型
持股股東
佔比
Sovereign Wealth Fund
1.29%
Investment Advisor
0.67%
Investment Advisor/Hedge Fund
0.55%
Hedge Fund
0.02%
Research Firm
0.01%
Other
97.45%
機構持股
更新時間: 7月1日 週二
更新時間: 7月1日 週二
報告期間
機構數
持股數
持股佔比
持股變動
2025Q2
60
9.07M
2.55%
-923.30K
2025Q1
60
9.08M
2.56%
-923.30K
2024Q4
59
8.93M
2.52%
-1.38M
2024Q3
56
8.37M
2.36%
-3.56M
2024Q2
55
7.62M
2.15%
-2.08M
2024Q1
54
5.00M
1.41%
-5.55M
2023Q4
56
5.70M
1.61%
-517.14K
2023Q3
51
1.23M
0.35%
-5.15M
2023Q2
46
1.39M
0.39%
-4.97M
2023Q1
43
1.38M
0.39%
-5.01M
查看更多
股東持股明細
名稱
持股數
佔比
持股變動
變動比例
公告日期
Mubadala Investment Company PJSC
4.60M
1.29%
--
--
Mar 31, 2025
Wellington Management Company, LLP
1.90M
0.54%
-396.50K
-17.24%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
1.50M
0.42%
+89.47K
+6.34%
Mar 31, 2025
DCF Advisers, LLC
751.58K
0.21%
+521.71K
+226.96%
Mar 31, 2025
Morgan Stanley Smith Barney LLC
63.92K
0.02%
+6.97K
+12.23%
Mar 31, 2025
AllianceBernstein L.P.
47.65K
0.01%
+28.58K
+149.81%
Jun 30, 2024
Tower Research Capital LLC
41.19K
0.01%
+41.19K
--
Mar 31, 2025
Lighthouse Investment Partners, LLC
37.55K
0.01%
-2.26K
-5.67%
Mar 31, 2025
Morgan Stanley & Co. LLC
24.12K
0.01%
-44.85K
-65.03%
Mar 31, 2025
Aperio Group, LLC
21.17K
0.01%
-11.04K
-34.28%
Mar 31, 2025
查看更多
持股ETF
更新時間: 7月6日 週日
更新時間: 7月6日 週日
機構名稱
佔比
iShares Biotechnology ETF
0.1%
ActivePassive International Equity ETF
0%
DFA Dimensional Intl Sustainability Core 1 ETF
0%
iShares Biotechnology ETF
佔比0.1%
ActivePassive International Equity ETF
佔比0%
DFA Dimensional Intl Sustainability Core 1 ETF
佔比0%
分紅派息
近5年累計派現
0.00
美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據
拆合股
公告日期
類型
比率
暫無數據
公告日期
類型
比率
暫無數據
